Product Description
Mechanisms of Action: NKT Stimulant
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Subcutaneous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Brazil | France | Germany | Hungary | Ireland | Korea | Malta | Peru | Portugal | Russia | Spain | Taiwan | Thailand | Turkey | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Exocrine Pancreatic Insufficiency|Hypotension
Phase 3: Calcinosis|Heart Valve Diseases|Aortic Valve Stenosis|Aortic Diseases
Phase 1: Bipolar Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ZnCl2 | N/A |
Completed |
Other |
2022-11-16 |
|
NCT04872140 | N/A |
Completed |
Anemia, Iron-Deficiency |
2022-06-30 |
|
CGM-ICU | N/A |
Completed |
Other |
2022-03-15 |
|
Toothpaste whitenning | N/A |
Completed |
Other |
2018-09-28 |